Is XOMA Royalty Corporation (XOMAP) overvalued? · P/E 25, rev $28.5M
XOMA Royalty Corporation (XOMAP) is a biotechnology company listed on NASDAQ.
This page asks whether XOMA Royalty Corporation (XOMAP) looks expensive on cached numbers — not a short thesis.
Latest reported XOMAP revenue for 2024-12-31 was $28.5M. Net income was -$13.8M. Revenue was up 498.7% from 2023-12-31 to 2024-12-31. XOMAP currently screens at market cap $0 and trailing P/E 25.4.
XOMAP currently screens at market cap $0 and trailing P/E 25.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next XOMAP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the XOMAP stock page for the full model, not this heading.
Not investment advice.